Plaque Psoriasis: Tapinarof Long Term Data

Jennifer Soung, MD, review long term data for tapinarof for the treatment of plaque psoriasis.

LindaStein Gold, MD: This was an interesting long-term study that we did with tapinarof, and the design was different from what we had seen in the past. Patients who completed the phase 3 trials were allowed to enroll in the long-term open-label study. Long-term studies are safety studies first, but we also tried to look at whether there was a remittive effect with tapinarof. We did that by allowing patients to treat until their skin became completely clear. That means a Physician Global Assessment score of 0, and that’s when we took them off the medication. It’s a safety study with no new red flags and the same safety profile that we saw with the phase 3. But when we looked at efficacy, we saw something interesting. For a nonsteroidal topical that you used once a day, almost 60% of patients at some point during that long-term study got to almost-clear skin, and 40% got to completely clear skin. Was this surprising to you for a topical, Jennifer?

Jennifer Soung, MD: I’m just happy we have this option for our patients. I was a little surprised because patients tell us that as soon as they stopped a topical steroid, within a couple of days, it would come back. They’re frustrated because this is a chronic disease, and we don’t have a long-term option. It’s so nice to have an effective topical when a patient becomes clear so that they can take a break and not have their psoriasis immediately recur.

LindaStein Gold, MD: We call this the remittive effect. We charted this, and it turns out that on average, patients had a 4-month durable remission off drug. This means that half of them had more than 4 months and half of them had less than 4 months. For the vast majority of patients, they went several months at least without any disease coming back. I’ve seen this in my patients. Jennifer, you’ve seen this as well.

Transcript edited for clarity

Related Videos
© 2023 MJH Life Sciences

All rights reserved.